

DARPA WASH Program Update

Brisbane, Australia, 29 June 2020 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provided an update on the US Defense Advanced Research Projects Agency (DARPA) Warfighter Analytics using Smartphones for Health (WASH) program. ResApp has been working with Lockheed Martin on the program since August 2018 and has provided the project with audio-based algorithms for measuring respiratory health.

The Reliable Analytics for Disease Indicators (ReADI) study has now been closed. This includes the audio-based work subcontracted to ResApp.

“We had made significant advances in audio-based algorithms for measuring health during the project,” said Tony Keating, CEO and Managing Director of ResApp. “We continue to develop these audio-based algorithms as they offer a unique opportunity for passively monitoring a person’s health.”

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx-EU, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts for ResApp Health

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.